Pardis Nematollahi1,2, Mina Shakery3, Amirhosein Kefayat3, Parvin Goli3. 1. Assistant Professor of Pathology, Department of Pathology, Cancer Prevention Research Center, Isfahan University of Medical Science Isfahan, Iran. 2. Fellowship of Hematopathology, Department of Pathology, Faculty of Medicine, Shiraz University of Medical Sciences Shiraz, Iran. 3. Department of Pathology, Isfahan University of Medical Science Isfahan, Iran.
Abstract
BACKGROUND: Identification of factors affecting prognosis in chronic lymphocytic leukemia (CLL) is important for risk stratification of patients. METHODS: In the present study, CD49d expression was analyzed by multi-color flow cytometry in 98 newly diagnosed and untreated CLL patients at the hematopathology ward. The patients were divided into two subgroups according to CD49d expression (30% cut off) and the association of this marker with the patients' clinicopathological properties were evaluated. RESULTS: In this study, CD49d expression exhibited significant association with the Rai stage of the disease (P<0.0001), CD38 status (P<0.0001), hemoglobin level (P=0.0006), and platelet count (P=0.0016). The CD49d-positive patients presented in higher stages in comparison with CD49d-negative patients. Although only 1% of the CD49d-negative patients were CD38-positive, this proportion for CD49d-positive group was 69%. However, no significant correlation was observed between CD49d expression and patients' age (P=0.2031), gender (P=0.8119), and absolute lymphocytes count (P=0.1073). CONCLUSION: Therefore, CD49d is a grateful biomarker with high association with clinicopathological parameters in CLL patients. IJPPP
BACKGROUND: Identification of factors affecting prognosis in chronic lymphocytic leukemia (CLL) is important for risk stratification of patients. METHODS: In the present study, CD49d expression was analyzed by multi-color flow cytometry in 98 newly diagnosed and untreated CLLpatients at the hematopathology ward. The patients were divided into two subgroups according to CD49d expression (30% cut off) and the association of this marker with the patients' clinicopathological properties were evaluated. RESULTS: In this study, CD49d expression exhibited significant association with the Rai stage of the disease (P<0.0001), CD38 status (P<0.0001), hemoglobin level (P=0.0006), and platelet count (P=0.0016). The CD49d-positive patients presented in higher stages in comparison with CD49d-negative patients. Although only 1% of the CD49d-negative patients were CD38-positive, this proportion for CD49d-positive group was 69%. However, no significant correlation was observed between CD49d expression and patients' age (P=0.2031), gender (P=0.8119), and absolute lymphocytes count (P=0.1073). CONCLUSION: Therefore, CD49d is a grateful biomarker with high association with clinicopathological parameters in CLLpatients. IJPPP
Authors: G Juliusson; D G Oscier; M Fitchett; F M Ross; G Stockdill; M J Mackie; A C Parker; G L Castoldi; A Guneo; S Knuutila; E Elonen; G Gahrton Journal: N Engl J Med Date: 1990-09-13 Impact factor: 91.245
Authors: R J Pratt; C M Pellowe; J A Wilson; H P Loveday; P J Harper; S R L J Jones; C McDougall; M H Wilcox Journal: J Hosp Infect Date: 2007-02 Impact factor: 3.926
Authors: Javier Redondo-Muñoz; Elizabeth Escobar-Díaz; Rafael Samaniego; María José Terol; José A García-Marco; Angeles García-Pardo Journal: Blood Date: 2006-07-13 Impact factor: 22.113
Authors: Valter Gattei; Pietro Bulian; Maria Ilaria Del Principe; Antonella Zucchetto; Luca Maurillo; Francesco Buccisano; Riccardo Bomben; Michele Dal-Bo; Fabrizio Luciano; Francesca M Rossi; Massimo Degan; Sergio Amadori; Giovanni Del Poeta Journal: Blood Date: 2007-10-24 Impact factor: 22.113
Authors: G Koopman; R M Keehnen; E Lindhout; W Newman; Y Shimizu; G A van Seventer; C de Groot; S T Pals Journal: J Immunol Date: 1994-04-15 Impact factor: 5.422